NCT02482311 2023-07-03
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
Clinical Trials
4 trialsNCT02593019 2021-03-19
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients
Samsung Medical Center
Phase 2 Completed
NCT02511795 2019-11-07
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02688907 2018-09-20
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation
Samsung Medical Center
Phase 2 Terminated